Wa'el Hashad Wa'el Hashad, CEO, Longeveron Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

Third Quarter, Recent Business Highlights and Upcoming Milestones Neurodegenerative Diseases Portfolio Alzheimer's Disease PRX012 ... approximately 260 patients in the ASCENT clinical trials Poster ...

confirming enrollment of individuals with mild-to-moderate DLB This poster is available on the Company's website Continued enrollment in Phase 2 START study (NCT05531656) in early Alzheimer's disease ...

For more information, or to sign-up to volunteer, go to https://www.concernedforthehungry.org. Fall-La-Palooza event aims to ...

Julianna LeMieux and Uduak Thomas discuss their time at the ASHG meeting in Denver and some of the trends that they are ...

The platform presentation entitled, “The MSA Atrophy Index: A Marker of Clinical Progression in Multiple System Atrophy”, was presented by Paula Trujillo Diaz, PhD, Research Assistant Professor, ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

AbbVie has an exclusive option to globally develop and commercialize AL002. Alector will deliver a data package resulting ...

MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ('Annovis' or the 'Company'), a clinical-stage drug ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease .

Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ETCompany ParticipantsMarissa Bych - Gilmartin GroupMaria Sainz ...